Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001707718 | SCV000618425 | uncertain significance | not provided | 2024-11-20 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000523025 | SCV000864107 | uncertain significance | not specified | 2017-02-06 | criteria provided, single submitter | clinical testing | Variant summary: The ALMS1 c.1451G>A (p.Gly484Asp alternative name c.1454G>A) variant involves the alteration of a non-conserved nucleotide and is predicted to be benign by 2/4 in silico tools (SNPs&GO not captured due to low reliability index). This variant was found in 14/120270 control chromosomes from ExAC, predominantly observed in the African subpopulation at a frequency of 0.001327 (13/9798). This frequency is slightly lower than the estimated maximal expected allele frequency of a pathogenic ALMS1 variant (0.0022361). No homozygotes have been reported in ExAC. It may be a rare polymorphism in African population, however no other supporting evidences are present at this time. The variant of interest has not, to our knowledge, been reported in affected individuals via publications and/or reputable databases/clinical diagnostic laboratories, nor evaluated for functional impact by in vivo/vitro studies. One internal sample carrying this variant also carries a pathogenic variant SCN5A c.2440C>T (p.Arg814Trp). Because of the absence of sufficient clinical information and the lack of functional studies, the variant is classified as a variant of uncertain significance (VUS) until additional information becomes available. |
Labcorp Genetics |
RCV000798208 | SCV000937810 | uncertain significance | Alstrom syndrome | 2022-08-23 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 485 of the ALMS1 protein (p.Gly485Asp). This variant is present in population databases (rs374663067, gnomAD 0.1%). This variant has not been reported in the literature in individuals affected with ALMS1-related conditions. ClinVar contains an entry for this variant (Variation ID: 449942). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Not Available"; Align-GVGD: "Not Available". The aspartic acid amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genetic Services Laboratory, |
RCV000523025 | SCV002071643 | uncertain significance | not specified | 2018-10-25 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002395252 | SCV002696895 | likely benign | Cardiovascular phenotype | 2022-02-25 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Fulgent Genetics, |
RCV000798208 | SCV002782698 | uncertain significance | Alstrom syndrome | 2022-01-10 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000798208 | SCV002080415 | uncertain significance | Alstrom syndrome | 2021-05-16 | no assertion criteria provided | clinical testing |